- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Intrauterine vacuum-induced hemorrhage control device controls bleeding for vaginal and cesarean deliveries
PPH causes 70,000 maternal deaths annually and 12% of U.S. maternal deaths (2017-2019). Obstetric hemorrhage affects physical, reproductive, and mental health.
The application of an intrauterine vacuum-induced hemorrhage control device resulted in rapid and effective bleeding control for both vaginal and cesarean deliveries, as demonstrated by a real-world study's findings published in the journal Obstetrics & Gynecology. The FDA cleared the JADA system in August 2020 for managing abnormal postpartum uterine bleeding.
A team of researchers led by Dr Goffman and colleagues assessed the real-world effectiveness and safety of a U.S. FDA-cleared intrauterine vacuum-induced-hemorrhage control device for managing PPH (postpartum hemorrhage).
This study was conducted at 16 American centres between October 2020 and March 2022. The primary outcome was evaluated based on treatment success, which was defined as controlling bleeding without additional treatment or recurrence. The study also examined other outcomes, such as blood loss, time to device insertion, indwelling time, bleeding recurrence, and time to bleeding control. The study evaluated treatment success and severe maternal morbidity by assessing blood loss before treatment and collected data on serious adverse events and adverse device effects to assess safety. The study summarized all outcomes by mode of delivery and treatment success by bleeding cause.
Key findings from the study are:
· 800 individuals were treated with the device ( (530 vaginal births, 270 cesarean births)
· 94.3% had uterine atony (alone or in combination with other causes).
· Median total blood loss at device insertion in vaginal and cesarean births was 1,050 mL and 1,600 mL, respectively.
· Across all bleeding causes, the treatment success rate vaginal and cesarean births was 92.5% and 83.7%, respectively. The Median indwelling time was 3.1 hours and 4.6 hours, respectively.
· In vaginal births and cesarean births, 14 SAEs (13 individuals) and 22 SAEs (21 individuals) were reported.
· Three SAEs were deemed possibly device or procedure-related.
· No uterine perforations or deaths were reported.
The FDA-cleared intrauterine vacuum-induced hemorrhage-control device effectively controlled bleeding in real-world settings for both vaginal and cesarean births. The safety profile was consistent with the registrational trial (NCT02883673), and no severe adverse device effects or SAEs were observed. This device serves as a crucial tool for managing life-threatening obstetric hemorrhage and may improve outcomes with timely utilization.
Reference:
Goffman et al. Real-World Utilization of an Intrauterine, Vacuum-Induced, Hemorrhage-Control Device. Obstetrics & Gynecology 142(5):p 1006-1016, November 2023. | DOI: 10.1097/AOG.0000000000005366
BDS, MDS in Periodontics and Implantology
Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751